Reblozyl Approved to Treat Anemia in ESA-Naive, Lower-Risk MDS
The approval was based on data from the phase 3 COMMANDS trial.
Diagnosis & Disease Information
Ivosidenib Gets Priority Review for IDH1-Mutated Relapsed or Refractory MDS
Ivosidenib produced an objective response rate of 83.3% in a phase 1 trial of patients with IDH1-mutated, relapsed or refractory MDS.
Risk of tMDS/AML After Common Lymphoid Neoplasms
Survivors of common lymphoid neoplasms have an increased risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia, data suggest.
Luspatercept Outperforms ESA in Adults With Lower-Risk MDS
Luspatercept appears more effective than epoetin alfa for treating anemia in patients with ESA-naïve, transfusion-dependent, lower-risk MDS.
Processed Red Meat Intake Linked to Increased Incidence of AML/MDS
Processed red meat intake is associated with an increased incidence of AML and MDS in a Japanese population, a study suggests.
Chest CT Prior to Allo-HSCT Deemed Beneficial for Spotting Abnormalities
Patients with abnormal chest CTs had worse overall survival, nonrelapse mortality, and pulmonary-related death after allo-HSCT.
ICC Recategorization Facilitates Risk Stratification of Myelodysplastic Syndrome
A distinct mutational landscape and worse outcomes were seen for patients with MDS/AML vs those with MDS.
Posoleucel Deemed Effective Against Viral Infections in Allogeneic HSCT Recipients
Posoleucel appears safe and effective for treating refractory viral infections occurring after allogeneic hematopoietic stem cell transplant.
Blood Supply Shortages Delay Transfusions for MDS Patients
Blood supply shortages can delay transfusions by an average of 4 days for patients with myelodysplastic syndromes, a survey suggests.
Registry Data Quantify 5-Year Survival in Lower-Risk MDS
About 40% of patients with lower-risk myelodysplastic syndromes die of the disease within 5 years, a study suggests.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...